Recently, clinical studies demonstrated that higher ACSL4 expression was related with enhanced sensitivity to neoadjuvant chemotherapy in breast cancer, leading to a better overall survival (Sha et al., 2021). This evidence concerns the gene ACSL4 and breast cancer.